Biosenic (BIOS.BR) Stock Price
Biosenic Price
Revenue has compounded at 0.0% per year over the past 3 years to 1.00 M EUR. Biosenic's net margin stands at -1,292.5%, up from -1,414.0% several years earlier.
Biosenic stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Biosenic business model & stock analysis
Frequently asked questions about Biosenic
The business model of Bone Therapeutics SA is focused on developing innovative cell therapy treatments for orthopedic conditions and bone diseases. Their approach involves the use of mesenchymal stromal cells (MSCs) derived from bone marrow, which have the potential to regenerate and repair damaged bone tissue. By harnessing the regenerative capabilities of MSCs, Bone Therapeutics aims to provide effective and safe solutions for patients suffering from debilitating bone disorders. This Belgian biotech company seeks to market their proprietary products globally, while conducting clinical trials and collaborating with scientific and medical communities to advance the field of cell therapy in orthopedics.
Bone Therapeutics SA is primarily active in the biotechnology and pharmaceutical industries.
The main competitors of Bone Therapeutics SA in the market include companies such as Medtronic PLC, Johnson & Johnson Services, Inc., Novartis AG, and Zimmer Biomet Holdings, Inc.
Bone Therapeutics SA is a Belgium-based biotechnology company specializing in the development of innovative regenerative therapies for orthopedic conditions. Founded in 2006, the company focuses on advanced cell-based therapies and biomaterials to support the healing process of bone and joint diseases. With a deep commitment to research and development, Bone Therapeutics aims to address unmet medical needs in areas such as osteoporosis, spinal fusion, and osteonecrosis. Leveraging their expertise in bone biology, Bone Therapeutics is dedicated to advancing the field of regenerative medicine and providing patients with effective and safe treatment options.
Bone Therapeutics SA, a leading biotechnology company, has achieved several significant milestones. Firstly, the company successfully completed Phase I/II trials for its breakthrough product, ALLOB®, a unique cell therapy for bone disorders. Additionally, Bone Therapeutics SA received clearance from regulatory authorities to initiate a Phase III clinical study for its advanced ALLOB® therapy, further validating its safety and efficacy. Moreover, the company forged strategic collaborations with renowned institutions, including the Musculoskeletal Transplant Foundation and the Santé Clinical Research Center. These partnerships enable Bone Therapeutics SA to leverage the expertise and resources required to advance their innovative bone therapies and bring them to market efficiently.
Bone Therapeutics SA is primarily present in multiple countries and regions. Some of the key areas where the company operates include Europe, particularly Belgium (where it is headquartered), France, and Luxembourg. With a strong focus on regenerative medicine and developing innovative therapies for bone-related disorders, Bone Therapeutics SA has established a presence in these regions to facilitate its research, clinical trials, and commercialization efforts. By leveraging its expertise and collaborations, the company aims to provide novel treatment options for patients with orthopedic and bone diseases in these countries and beyond.
Bone Therapeutics SA is a leading biotechnology company committed to improving patients' lives by developing innovative treatments for orthopedic conditions and bone diseases. Guided by a strong corporate philosophy, Bone Therapeutics SA values scientific excellence, collaboration, and patient-centricity. The company aims to provide revolutionary therapies that harness the regenerative potential of bone for repairing and preventing bone-related problems. With a focus on translational medicine and cutting-edge research, Bone Therapeutics SA strives to deliver breakthrough solutions and improve the quality of life for patients suffering from musculoskeletal disorders.
9 analysts currently rate the Biosenic stock: 0 recommend buying, 3 holding and 6 selling.
The Biosenic share (BIOS.BR) is listed on 6 stock exchanges, including: London (0R55.L), Frankfurt (BT1.F), Düsseldorf (BT1.DU).
Bone Therapeutics SA is a biopharmaceutical company that specializes in the development of innovative cell therapies for bone and joint diseases. The company focuses on rapid market introduction of therapies based on selected and well-characterized cell types that provide clinically significant improvement. The company is divided into two business segments – bone and joint replacement products, and cell therapies. In the first segment, they offer products such as Artebone and Allob, which are aimed at replacing bone and joint tissue. Artebone is a natural bone matrix derived from bovine bone and regenerates into new bone through the body's own regeneration process. Allob, on the other hand, is an allogeneic bone marrow derivative obtained from human donor bones and is currently being tested in clinical trials for the treatment of bone defects and osteonecrosis. In the second business segment, Bone Therapeutics SA is developing cell therapies. They have two therapies in clinical development. Allob-MSC1 is an allogeneic combination of bone marrow-derived mesenchymal stromal cells (MSCs) and the aforementioned Allob product, which is used for the treatment of osteonecrosis. The product is currently in Phase III of clinical trials. JTA-004 is an injection consisting of leukocyte-derived mesenchymal stem cells (LMSCs) and is being developed for the treatment of knee osteoarthritis. The product has already been successfully tested in a Phase IIa study and is currently in Phase III of clinical trials. Bone Therapeutics SA works closely with academic and clinical partners and is building a network of collaborations to accelerate the development of cell therapies for orthopedic indications. The company has also entered into several licensing agreements with other companies to support its clinical trials with innovative techniques and products. Overall, Bone Therapeutics SA aims to take a leading position in the field of cell therapies for bone and joint diseases. The company has developed unique products and advanced technologies to address the clinical gaps in this area and bring significant improvements to patients. Bone Therapeutics SA strives for the rapid market introduction of its products and works hard to develop safer and more effective cell therapies for orthopedic indications.
The revenue cannot currently be calculated for Biosenic.
The profit cannot currently be calculated for Biosenic.
The P/E ratio cannot be calculated for Biosenic at the moment.
The P/S cannot be calculated for Biosenic currently.
The Eulerpool Quality Score for Biosenic is 2/10.
The ISIN of Biosenic is BE0974280126. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Biosenic is A14NHV. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Biosenic is BIOS.BR. The ticker symbol is used to trade Biosenic shares on the stock exchange.
Biosenic stock
Biosenic Peer Group
Biosenic Ticker
Biosenic FIGI
All fundamentals and in-depth analysis of Biosenic
Our stock analysis for Biosenic stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Biosenic. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.